# A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)

> **NCT03979313** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 3012 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **DRUG:** MEDI8897
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03979313
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-23
- **Primary completion:** 2021-03-11
- **Final completion:** 2023-03-21
- **Target enrollment:** 3012 (ACTUAL)
- **Last updated:** 2024-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03979313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03979313, "A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03979313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*